Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
1.520
+0.010 (0.66%)
At close: Nov 14, 2025, 4:00 PM EST
1.500
-0.020 (-1.32%)
After-hours: Nov 14, 2025, 4:26 PM EST
Prelude Therapeutics Market Cap
Prelude Therapeutics has a market cap or net worth of $115.72 million as of November 14, 2025. Its market cap has increased by 6.68% in one year.
Market Cap
115.72M
Enterprise Value
76.33M
1-Year Change
6.68%
Ranking
Category
Stock Price
$1.52
Market Cap Chart
Since the IPO on September 25, 2020, Prelude Therapeutics's market cap has decreased from $806.64M to $115.72M, a decrease of -85.65%. That is a compound annual growth rate of -31.48%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 13, 2025 | 114.96M | 18.85% |
| Dec 31, 2024 | 96.73M | -70.04% |
| Dec 29, 2023 | 322.85M | 12.32% |
| Dec 30, 2022 | 287.43M | -50.22% |
| Dec 31, 2021 | 577.35M | -80.97% |
| Dec 31, 2020 | 3.03B | 276.02% |
| Sep 25, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 885.19B |
| Johnson & Johnson | 466.99B |
| AbbVie | 397.96B |
| UnitedHealth Group | 296.62B |
| AstraZeneca | 275.02B |
| Novartis AG | 249.68B |
| Merck & Co. | 225.74B |
| Abbott Laboratories | 220.84B |